Skip to main
WGS
WGS logo

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 11%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings Corp shows a strong positive outlook driven by substantial growth in its whole exome and genome (WES/WGS) testing, with a remarkable 65% year-over-year increase in core revenue during the recent quarter. The company has strategically realigned its sales focus towards pediatric neurologists, which could further enhance its revenue trajectory, supported by an anticipated increase in average selling prices (ASPs) and gross margins (GMs). Notably, GeneDx raised its 2025 revenue guidance to $425-428 million, reflecting confidence in achieving a +39%-40% year-over-year growth, backed by the upward trend in testing volumes and ASPs.

Bears say

GeneDx Holdings Corp is projected to experience a substantial cash burn of ~$2 million per quarter this year, indicating a potential liquidity strain. The company's high denial rate of 45% as of Q3 2024, coupled with reliance on ongoing relationships with third-party payers for adequate reimbursement, presents a significant risk to its commercial success and future revenue generation. Additionally, the reduction in the sales force from 65 to 54 representatives reflects a strategic realignment aimed at cutting unprofitable accounts, yet it also highlights challenges in sustaining growth and market penetration.

WGS has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 11% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Buy based on their latest research and market trends.

According to 9 analysts, WGS has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.